医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meiji Seika Pharma to Launch Two Products from Santen Pharmaceutical Co., Ltd. in Indonesia

2019年08月07日 AM10:00
このエントリーをはてなブックマークに追加


 

JAKARTA, Indonesia

Meiji Seika Pharma Co., Ltd. “Meiji” has announced that it launched the following two products from Santen Pharmaceutical Co., Ltd. “Santen” in Indonesia, based on a working business agreement that Meiji entered in November of 2018 with Santen.

Dry-eye treatment
DIQUAS ophthalmic solution 3%
(Diquafosol Sodium)

Glaucoma and ocular hypertension treatment
TAFLOTAN ophthalmic solution 0.0015%
(Tafluprost)

Based on the working business agreement with Santen, these products will be marketed in Indonesia by Meiji’s affiliated subsidiary, PT. Meiji Indonesian Pharmaceutical Industries “PT. Meiji”. PT. Meiji established a new marketing team specialized on ophthalmic treatments, and Santen will support their marketing activities. Moving forward, PT. Meiji will continue to add more products and expand the product lineup. PT. Meiji and Santen work together to expand market share in Indonesia for ophthalmic products.

Meiji and Santen, through the marketing of ophthalmic treatments in Indonesia, are contributing to the health of the peoples of ASEAN countries.

About Meiji Seika Pharma Co., Ltd
Address: Chuo-ku, Tokyo Japan
President and CEO: Daikichiro Kobayashi
https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

About Santen Pharmaceutical Co., Ltd.

Address: Kita-ku, Osaka Japan
President and CEO: Akira Kurokawa
https://www.santen.com/en/

About PT. Meiji Indonesian Pharmaceutical Industries
Established: 1974
Address: Jalan Prof. Dr. Soepomo No. 40, Tebet, Jakarta Selatan, 12870 Indonesia
President Director: Masanobu Sato
Employees: 799, as of March, 2019
Parent Company: Meiji Seika Pharma Co., Ltd.

Scope of Business: Manufacture, sales, and export of medical products and materials
https://meiji.co.id/id

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190806005344/en/

CONTACT

Meiji Seika Pharma Co., Ltd.

Masashi Ohnishi

Public Relations

pr-pharma@meiji.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease